Page 20 - SFHN0120FINALUF.qxp_SFHN 0608 Friday 5.0

ONCOLOGY UPDATE in South Florida ...ONCOLOGY UPDATE in South Florida

Innovative Clinical Research at Holy Cross Hospital

Physician investigators at Holy to develop new Neuroscience Research potential treatments for wound healing
Cross Hospital's Research targets for cancer Dr. Eduardo Locatelli recently for chronic diabetic foot wounds.
Institutes have expanded their treatment to announced that the Phil Smith Holy Cross was awarded a $500,000
efforts to offer innovative research ensure the best Neuroscience Institute at Holy Cross Innovation Grant by Trinity Health to
studies close to home for patients possible long-term Hospital has been selected for the study accelerated healing of acute and
who live in South Florida. The outcomes and to HEALEY Amyotrophic Lateral Sclerosis chronic wounds in both diabetic and
hospital’s research programs now prevent cancer (ALS) Platform Trial by the Sean M. nondiabetic mice. These studies, per-
include clinical trials in cardiovas- recurrence. Healey & AMG Center at Massachusetts formed in partnership with the MGH
cular disease, cancer, orthopedics, Additionally, General Hospital. Vaccine and Immunotherapy Center
neuroscience, pain management, Holy Cross The Sean M. Healey & AMG Center, in (VIC), have investigated how the appli-
and women's health, among oth- Hospital Research collaboration with the Northeast ALS cation of mature B lymphocytes has the
ers. Institutes recently Consortium (NEALS), is launching the potential to improve the quality of regen-
completed negoti- first platform trial for amyotrophic later- erated tissue and reduced scarring. The
Oncology Research BY PAUL PAPAGNI, JD ations to become al sclerosis (ALS). The goals of this VIC research team reported the results of
Microbiome research, which the third National groundbreaking project are to greatly these studies in the Journal of Wound
involves the study of the millions Cancer Institute accelerate the timelines towards effective Repair and Regeneration (18 September
of microbes that make up our gut diges- Community Oncology Research ALS treatments and provide greater trial 2017), describing how application of
tive tract, is expected to play a major role Program (NCORP) in the State of access for all those affected by this dis- mature B lymphocytes greatly accelerat-
in diagnostics, prevention and treatment Florida. NCORP is a national network of ease. ed the healing of acute and chronic
of a number of various disease condi- investigators, cancer care providers, and This builds upon Holy Cross Hospital’s wounds in both diabetic and nondiabetic
tions. Recently, we opened a study devel- other institutions that provide cancer expanded, formalized relationship with mice. The article also describes
oped by Dr. Omar Rashid and supported clinical trials and cancer care research to Massachusetts General Hospital, which improved quality of regenerated tissue
by the Community Foundation of the local communities. Holy Cross provides patients with access to first- and reduced scarring. Additional studies
Broward to evaluate the interaction Hospital Cancer Research will become class research and leading-edge clinical are ongoing.
between patient genetic characteristics, an NCORP site in partnership with the trials and treatments at the Phil Smith
patient immune responsiveness, tumor Michigan Cancer Research Consortium Neuroscience Institute. Paul Papagni, JD, serves as the Executive
genetic characteristics and gut microbio- and our parent company Trinity Heath. The HEALEY ALS Platform Trial will Director of Research at Holy Cross
me genetic characteristics, in the context Holy Cross Cancer Research is presently begin in early 2020. Hospital. He can be reached at
of a patient's cancer clinical treatment. designated as an ECOG-ACRIN member paul.papagni@holy-cross.com
This combination of genetic testing and site. This new NCORP designation will Diabetes Research or (954) 229-8553.
microbiome analysis provides a snapshot provide patients with access to over 110 Holy Cross Hospital also holds patents
before therapeutic interventions in order NCI supported studies. for the use of B lymphocytes to develop

Y
J Jumpmp Start Yourr New Year!
Y

1, 5, 7, 14 && 21 Da y, All-InInnclusiv e PackP a ages

• Luxur y oc eanffront property right dw
er:
WeOffeeeOff e fer:
e
W
B
d evegan cuisine: bsine: e: b
a
PlPlant-Basedddd ii bb ast, l lunc h
•
W at a er-Only Fastingg

AfA ull da y o facctivitiesctivitiiet ies aa e ercisciseclses
and fan
Juic e Cleanses
ewelln ss leesss esellnees leee
• o or o o ormati ewativ ew e w o
Plant-Based Food Prog amsgr
nddeeeeeeeee
• o or pam n x xpp b
or ppapampmppering andpe
C on erencenf es and Speciall Ev ents
• MMeMe all upe visesed bbere i s y Dr rFr an o
• • 3 ea sooso fInnnccncncccrededcredibblebleRRele ReeRRcr le le ts!!
Loc atio
U e Ces e CCCCC e OSOSPO PIIIOOOSPPPIPITITAHHHHHOHOH P PIII ALLL 0LLL 20 W W W y ynd Beacch o ort
A A A A A A AL
2 2 20000
AL
Coodeedeoooo eeoddedoo
IT I I I I AALALA
AL
ort
ndham Deerfimddham Deereem eee
2 209
2 2
2 909960
war
y y
2 2 00 0T0 TTooT o ow a a ard AnAnAd AnAAA n 55y 55y 555 1 Day aaay PP a a
4 1
D D D De ld BBeB 34444
o o o to bee cccee e
d
offfff
Not t ttoo o o o bbmbbbbiinin diiinineddd t ithhh th an oo heehtotho heho ho h err e er roo e e e f f fe t t o aava v
20
02202002020
Ex
Ex
Expxpx rpx sJanununuuuaauuu y r 31,21, 231, 2311, 22313 200
TIOONS CONT
VAA
FOR RESERV AT TA CT:
A
fo
fe
e
Direect (954) 637-4674 | Cell (561) 715-1774 | inf o@BalanceForLif eFlorida.c omm
BallanceForLif eFlorida.c omm
fe
20 January 2020 southfloridahospitalnews.com South Florida Hospital News